Last articles

FDA for the withdrawal of midodrine

Author : Pierre Allain Date : 2010-10-25

FDA, in a note dated August 16, 2010, asks for the withdrawal from the market of midodrine (ProAmatine*) because its efficacy on clinical events has not been confirmed.

More information about midodrine and other vasoconstrictor agents with alpha-1 adrenergic effect.

Your turn
User session
Bookmark, share this page
Bookmark and Share

© 2000-2019 CdM Editions / P. Allain. All rights reserved
Pharmacorama Charter